Ilicicolin A Exerts Antitumor Effect in Castration-Resistant Prostate Cancer Via Suppressing EZH2 Signaling Pathway

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Prostate cancer (PCa) progression and drug resistance are significant challenges in treatment.
• Enzalutamide (ENZ) resistance is a major obstacle in metastatic castration-resistant prostate cancer (CRPC).
• The role of enhancer of zeste homolog 2 (EZH2) in PCa and its interaction with ENZ are not fully understood.

Purpose of the Study:

• To investigate the mechanism of action of Ilicicolin A (Ili-A) in CRPC.
• To explore the potential of Ili-A in overcoming enzalutamide resistance.
• To determine if Ili-A can be used in combination therapy for CRPC.

Main Methods:

• RNA-sequencing to identify pathways involved in PCa proliferation.
• Western blotting to assess protein levels of EZH2.
• Chromatin immunoprecipitation assays to study EZH2 binding to promoter regions.
• In vivo studies using CRPC cancer models to evaluate combination therapy efficacy.

Main Results:

• RNA-sequencing identified the EZH2 pathway as crucial for PCa proliferation.
• Ili-A treatment significantly reduced EZH2 protein levels, leading to transcriptional changes.
• Ili-A inhibited the binding of EZH2 to promoter regions of AR/polo-like kinase-1/aurora kinase A.
• Ili-A demonstrated synergistic anticancer effects when combined with enzalutamide in CRPC models.

Conclusions:

• Ilicicolin A targets the EZH2 pathway in prostate cancer.
• Ili-A can overcome enzalutamide resistance in CRPC by modulating EZH2 activity.
• Combination therapy with Ili-A and enzalutamide shows promise for treating CRPC.